Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/157939
Full metadata record
DC FieldValueLanguage
dc.creatorStephanie Andrade
dc.creatorDébora Nunes
dc.creatorMeghna Dabur
dc.creatorMaria João Ramalho
dc.creatorMaria do Carmo Pereira
dc.creatorJoana A Loureiro
dc.date.accessioned2024-04-09T23:06:43Z-
dc.date.available2024-04-09T23:06:43Z-
dc.date.issued2023
dc.identifier.issn1999-4923
dc.identifier.othersigarra:667369
dc.identifier.urihttps://hdl.handle.net/10216/157939-
dc.description.abstractNeurodegenerative diseases are caused by the gradual loss of neurons' function. These neurological illnesses remain incurable, and current medicines only alleviate the symptoms. Given the social and economic burden caused by the rising frequency of neurodegenerative diseases, there is an urgent need for the development of appropriate therapeutics. Natural compounds are gaining popularity as alternatives to synthetic drugs due to their neuroprotective properties and higher biocompatibility. While natural compounds' therapeutic effects for neurodegenerative disease treatment have been investigated in numerous in vitro and in vivo studies, only few have moved to clinical trials. This article provides the first systematic review of the clinical trials evaluating natural compounds' safety and efficacy for the treatment of the five most prevalent neurodegenerative disorders: Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington's disease.
dc.language.isopor
dc.rightsrestrictedAccess
dc.titleTherapeutic Potential of Natural Compounds in Neurodegenerative Diseases: Insights from Clinical Trials
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoFaculdade de Engenharia
dc.identifier.doi10.3390/pharmaceutics15010212
Appears in Collections:FEUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
667369.pdf
  Restricted Access
612.42 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.